Eli Lilly and Company (LLY) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer
$1,373.70 +6.63% NYSE • Public Delayed / 60s Snapshot
Eli Lilly and Company (LLY) earns a Roarable Rating of B (Buy) with 72/100 RQD Confidence. High-quality cash engine (84% profit margin, 32% return on capital) with steady institutional support. Even if the broader market gets choppy, the company’s underlying cash engine and big-money support put the odds in buyers’ favor.
ROARABLE B • BUY
Cap $1.33T
INTERACTIVE SCENARIO DECK:
RQD QUANT TACHOMETERBUY • B
2-of-3 JEV AI Jury Bullish
Cash
SEC
Whale
5-PILLAR SNOWFLAKE RADARRw B+ · Rk C
Each axis scored 0–20
12M PRICE TARGET CONE+23% Base Target
WHALE OPTIONS TUG-OF-WAR:45% Call Buyers ($5.4M)
55% PutsMax Pain: $1,200.00
SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT
Explore All 13F & Congress Whales →LLY Smart-Money Thermometer: HEAVY INSIDER & 13F ACCUMULATION
▲ Disclosed Buys: 6 ($1.25B)▼ Disclosed Sales: 10 ($543.9M)
Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (LLY)
| Filer / Title | Category | Side | Shares | $ Value | Filed |
|---|---|---|---|---|---|
| Duquesne Family Office (Stanley Druckenmiller)13F-HR Global Macro Family Office // CIK 0001536411 | HEDGE_FUND | BUY | 275,000 | $325.5M | 2026-10-15 |
| Jonsson PatrikSEC Form 4 Open-Market Officer / Director | INSIDER | SELL | 6,500 | $7.6M | 2026-08-18 |
| Zakrowski Donald ASEC Form 4 Open-Market Officer / Director | INSIDER | SELL | 2,000 | $2.4M | 2026-08-11 |
| Hakim AnatSEC Form 4 Open-Market Officer / Director | INSIDER | SELL | 5,000 | $6.0M | 2026-08-10 |
| Citadel Advisors (Ken Griffin)13F-HR Multi-Strategy Institutional Manager // CIK 0001423053 | HEDGE_FUND | BUY | 310,000 | $376.3M | 2026-07-22 |
| Renaissance Technologies13F-HR Medallion Quantitative Manager // CIK 0001037389 | HEDGE_FUND | BUY | 265,000 | $321.7M | 2026-07-20 |
| Yuffa IlyaSEC Form 4 Open-Market Officer / Director | INSIDER | SELL | 2,500 | $2.9M | 2026-06-11 |
| Lilly Endowment IncSEC Form 4 Open-Market Officer / Director | INSIDER | SELL | 15,828 | $15.8M | 2026-05-07 |
| Rep. Nancy PelosiU.S. House Representative (CA-11) // STOCK Act PTR | POLITICIAN | BUY | 1,200 | $1.2M | 2026-03-10 |
| Rep. Mark GreenU.S. House Homeland Security Chair (TN-07) // STOCK Act PTR | POLITICIAN | BUY | 480 | $484.6K | 2026-03-09 |
| Berkshire Hathaway (Warren Buffett)13F-HR Value Conglomerate & Float Manager // CIK 0001067983 | HEDGE_FUND | BUY | 210,000 | $226.9M | 2026-01-16 |
| Lilly Endowment IncSEC Form 4 Open-Market Officer / Director | INSIDER | SELL | 292,148 | $322.4M | 2026-01-08 |
| Lilly Endowment IncSEC Form 4 Open-Market Officer / Director | INSIDER | SELL | 1,390 | $1.5M | 2026-01-06 |
| Lilly Endowment IncSEC Form 4 Open-Market Officer / Director | INSIDER | SELL | 3,593 | $3.9M | 2025-12-30 |
| Lilly Endowment IncSEC Form 4 Open-Market Officer / Director | INSIDER | SELL | 2,869 | $3.1M | 2025-12-29 |
🔴 SUNDAY NIGHT PREP • 7:00 PM ETHosted Live by Perry Belcher + Senior Cash-Flow & Income Strategist
Cash-Fortress Compounders: Collecting Safe Yield & Upside in LLY & Top A-Rated Leaders
- ✓12-month Bull/Base/Bear fair-value walkthrough on LLY and its top sector rival
- ✓The Top 5 Roarable A-Rated cash compounders with heavy executive & 13F accumulation
- ✓Includes free daily Morning Market Weather & signal upgrade/downgrade dispatch
RQD INSIDER CLUB UPGRADE$49/YEAR
Want Plain-English AI Custom Indicators, Daily Pro Trader Video Clips & SMS Crash Alerts?
LLY // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +47.15%▲ RESISTANCE BREAKOUT
2026-10-30O $1,286.4H $1,449.7L $1,260.3C $1,417.5VOL 15.63M
RES: $1,364.7SMA50: $1,197.1SMA200: $1,091.2
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
LLY Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
-0.53% YoY Shares
SEC XBRL FY2024 → FY2025: Net share cannibal / buyback tailwind.
Reverse-DCF Expectations Hurdle (#30)
35.5%/yr Implied 5Y Growth
vs. +45.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
DEVELOPING · Incretin Capacity Base Reclaim
Trigger: $1452.98 • Invalidation: $1349.50
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
WST → LLY Confirmed Filing
West Pharmaceutical Services manufactures NovaPure fluoropolymer-coated elastomer plungers and cartridge seals required inside sterile single-dose and multi-dose GLP-1 auto-injector pens.
TMO → LLY Confirmed Filing
Following Novo Holdings acquisition of Catalent fill-finish sites, Eli Lilly and rival GLP-1 developers increasingly rely on Thermo Fisher Patheon sterile fill-finish lines to clear injectable pen bottlenecks.
LLY → NVO Confirmed Filing
Eli Lilly dual GIP/GLP-1 agonist tirzepatide (Zepbound/Mounjaro) demonstrated superior head-to-head weight loss vs. Novo Nordisk semaglutide (Wegovy) in SURMOUNT-5, intensifying PBM rebate competition.
AI Analyst Theses, Washington Policy & Company Video
💡 Friday Evidence Audit: What Confirmed, What Stalled & Where Options Overpriced the Move (felix-orven)
💡 Starter Kit: Cash-Fortress Zero-Dilution Compounders (ellis-vennor)
🏛️ COMMENT_RULEMAKING: CMS Contract Year Medicare Advantage Capitation Benchmark & Part D GLP-1 Coverage Rulemaking (Centers for Medicare & Medicaid Services (HHS — 42 CFR Parts 422 & 423))
🎬 No recent verified company-specific video clip queued for LLY today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
LLY Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDAre LLY insiders and hedge funds buying or selling?
Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies LLY leadership and institutional positioning as: HEAVY INSIDER & 13F ACCUMULATION.